Bridging the Gaps

New Directions and Practice Impacting Recommendations in Multiple Sclerosis
Faculty presenters: Erin Longbrake, MD, PhD (Meeting Chair and Publication Editor); Stephen Krieger, MD; Carrie M. Hersh, DO, MSc, FAAN; Jens Kuhle, MD, PhD; Pascal Sati, PhD; Robert T. Naismith, MD; Fredrik Piehl, MD; Riley Bove, MD; and Ahmed Z. Obeidat, MD.
This NeurologyLive supplement comprises 3 articles that review the evolving biological understanding of multiple sclerosis (MS) and the associated implications for treatment. The publication also explores emerging biomarkers in MS as well as the latest ideas on the use of disease-modifying therapies, including scenarios for starting, switching, or stopping immunotherapy.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 2a INFORM-MS Trial to Study Anti-CD3 Agent Foralumab in Nonactive Secondary Progressive MS
2
Gene Therapy AMT-130 Meets End Points in Huntington Study, FDA Submission to Follow
3
Phase 3 Topline Results Show Rituximab Noninferior to Cladribine in Reducing New or Enlarging Brain Lesions in Relapsing-Remitting MS
4
Leveraging Artificial Intelligence to Extract Real-World Insights in Multiple Sclerosis: Rebekah Foster, MBA, and John Foley, MD, FAAN
5